Qiagen N.V. (NYSE:QGEN) Receives $43.93 Average Price Target from Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have been given an average recommendation of “Hold” by the fourteen research firms that are covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $43.9250.

Several brokerages recently commented on QGEN. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 price target on shares of Qiagen in a research note on Thursday, August 6th. Stifel Nicolaus set a $40.00 price objective on Qiagen in a research note on Friday, August 7th. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the company a “hold” rating in a report on Thursday, June 25th. TD Cowen restated a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. Finally, Barclays set a $40.00 target price on shares of Qiagen and gave the stock an “equal weight” rating in a report on Friday, August 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Danske Bank A S acquired a new stake in Qiagen during the 3rd quarter valued at $36,000. Manchester Capital Management LLC acquired a new position in Qiagen in the fourth quarter worth $42,000. Global Retirement Partners LLC boosted its stake in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares in the last quarter. Hilltop National Bank bought a new stake in shares of Qiagen during the second quarter worth $50,000. Finally, Advisory Services Network LLC bought a new stake in shares of Qiagen during the third quarter worth $64,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Trading Down 0.3%

Shares of Qiagen stock opened at $43.36 on Tuesday. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The firm has a market capitalization of $8.94 billion, a PE ratio of 22.22, a price-to-earnings-growth ratio of 4.33 and a beta of 0.63. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The company’s fifty day moving average price is $41.98 and its two-hundred day moving average price is $40.30.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same period in the previous year, the business earned $0.60 EPS. The firm’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts expect that Qiagen will post 2.43 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.